Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Startups & Funding

Isomorphic Labs Raises $5 Billion to Move AI-Designed Drugs Into Trials

Isomorphic Labs, the DeepMind spinout building an AI drug-design engine, has raised $5 billion in a Series C round led by Greenoaks and Sequoia to take its oncology and immunology candidates into clinical trials.

By
Tom Whitfield
Filed
Channel
Startups & Funding
Read
2 min read

Isomorphic Labs, the AI drug-discovery company spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C round to push its drug candidates into clinical trials. The round arrives just months after a $2.1 billion Series B closed in May, and Bloomberg reported this month that the company was seeking the funding at a valuation of roughly $50 billion. Isomorphic did not disclose its final valuation.

Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz joined as a new investor, alongside returning backers that include Alphabet's venture arms GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.

What does the company actually build?

Isomorphic Labs operates an AI drug-design engine that runs a collection of simulation models across multiple areas of chemistry. The system helps researchers design drug candidates computationally rather than through purely experimental screening.

The work builds on AlphaFold, the DeepMind protein-folding model that predicts the 3D structure of proteins from their genetic sequence alone. The company said its pipeline has produced "positive preclinical results" in oncology and immunology. It has also signed partnerships with three major pharmaceutical companies: Eli Lilly, Novartis and Johnson & Johnson.

The mechanism is straightforward in outline. A model that can predict how a protein folds gives researchers a structural target; simulation models then search chemical space for molecules that interact with that target. The $5 billion will fund further development of that engine and an expansion into additional types of medicine.

Why did the CEO change jobs?

The Series C is the first fundraise since Demis Hassabis, Isomorphic's founder and CEO, stepped down as head of DeepMind to concentrate on drug discovery. He retains a chairman role at DeepMind.

Hassabis and John Jumper, then a director at DeepMind, shared the Nobel Prize in chemistry for the AlphaFold work. That prize anchors the scientific credibility behind the company's approach and helps explain why investors are committing capital at this scale before a single Isomorphic drug has reached human trials.

What happens next?

The immediate test is clinical. Preclinical results in oncology and immunology must now survive human trials, the stage where most drug candidates fail regardless of how they were designed. The fresh capital buys the company years of runway to run those trials, refine its design engine and broaden its therapeutic scope while its pharma partnerships supply validation and, potentially, revenue.

Source: techcrunch.com

Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Staff writer covering companies, deals and strategy in Semiconductors, chip manufacturing, hardware, AI compute at Chip Dispatch.

1,026 articles

Related articles

« Previous article